ACRS - Aclaris Therapeutics, Inc. Stock Analysis | ConvictionStocks
Healthcare
Aclaris Therapeutics, Inc.
ACRS
$5.64+6.02%
Price is delayed.
Add to watchlist
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics is a drug company developing treatments for immune and inflammatory diseases like eczema, asthma, and autoimmune conditions. The company has several experimental medicines in clinical trials, which are studies to test whether drugs work safely in people. Most of their treatments work by blocking proteins in the immune system that cause inflammation. The company is based in Pennsylvania and was founded in 2012.
1D1W1M3M1Y5YMAX
Loading chart...
Chart powered by TradingView Lightweight Charts
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
What each number means, in plain English, with the Wall Street name where the two differ.
A plain-English summary of the company.
How many analysts cover it, and the count behind each rating.